227623-26-9

Basic information

• Product Name: 5-TERT-BUTYL-2-(4-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE
• Synonyms: 5-TERT-BUTYL-2-(4-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE;BUTTPARK 30\09-73;1H-Pyrazol-5-aMine, 3-(1,1-diMethylethyl)-1-(4-Methoxyphenyl)-;3-(tert-Butyl)-1-(4-Methoxyphenyl)-1H-pyrazol-5-aMine;3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazole
• CAS NO: 227623-26-9
• Molecular Formula: C₁₄H₁₉N₃O
• Molecular Weight: 245.32
• Mol File: 227623-26-9.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 5-TERT-BUTYL-2-(4-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-TERT-BUTYL-2-(4-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE(227623-26-9)
• EPA Substance Registry System: 5-TERT-BUTYL-2-(4-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE(227623-26-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 227623-26-9(Hazardous Substances Data)

Usage

General Description

5-Tert-butyl-2-(4-methoxy-phenyl)-2H-pyrazol-3-ylamine is a chemical compound with the molecular formula C14H20N2O. It is a pyrazole derivative with a tert-butyl group and a 4-methoxyphenyl group attached to the pyrazole ring. 5-TERT-BUTYL-2-(4-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE is commonly used as a building block in organic synthesis and drug discovery research. It has been studied for its potential pharmacological properties, including its ability to modulate the activity of certain enzymes and receptors in the body. However, further research is needed to fully understand the biological effects and potential applications of this compound.

Upstream product

• 59997-51-2 trimethylacetylacetonitrile 
• 3471-32-7 4-Methoxyphenylhydrazine 
• 19501-58-7 4-methoxyphenylhydrazine hydrochloride 

Downstream Products

• 1071964-51-6 1-(3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)-3-(5-(2-morpholinoethoxy)-2H-chromen-8-yl)urea 
• 1254713-66-0 (3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)methanamine 
• 1255040-45-9 N-((3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)methyl)-2-(3-fluoro-4-(methylsulphonamido)phenyl)propanamide 
• 725686-65-7 1-(5-tert-butyl-2-(p-methoxy-phenyl)-2H-pyrazol-3-yl)-3-(4-chlorophenyl)urea 
• 940875-74-1 [5-tert-butyl-2-(4-methoxy-phenyl)-2H-pyrazol-3-yl]-carbamic acid 2,2,2-trichloro-ethyl ester 
• 1443248-15-4 (5-tert-butyl-2-{4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-N,N-bis-carbamic acid 2,2,2-trichloro-ethyl ester 
• 1352798-84-5 1-(3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)-3-(4-((3-oxo-3,4-dihydropyrido[3,2-b]pyrazin-8-yl)methoxy)naphthalen-1-yl)urea 
• 1352798-83-4 1-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)-3-(4-((7-oxo-7,8-dihydropteridin-4-yl)oxy)naphthalen-1-yl)urea 
• 1352798-80-1 1-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)-3-(2,3-dichloro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea 
• 1352798-70-9 1-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)-3-(2,3-dichloro-4-((1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)oxy)phenyl)urea 
• 1352798-69-6 1-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)-3-(4-((1-isopropyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)oxy)naphthalen-1-yl)urea 
• 1352798-68-5 1-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)-3-(4-((1-ethyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)oxy)naphthalen-1-yl)urea 
• 1352798-67-4 1-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)-3-(4-((1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)oxy)naphthalen-1-yl)urea 
• 1352798-66-3 1-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)-3-(4-((2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)oxy)naphthalen-1-yl)urea 

Relevant articles and documents

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists

A series of 1-substituted 3-(t-butyl/trifluoromethyl)pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides were investigated for hTRPV1 antagonism. The structure activity relationship indicated that the 3-chlorophenyl group at the 1-position of pyrazole was the optimized hydrophobic group for antagonistic potency and the activity was stereospecific to the S-configuration, providing exceptionally potent antagonists 13S and 16S with Ki(CAP) = 0.1 nM. Particularly significant, 13S exhibited antagonism selective for capsaicin and NADA and not for low pH or elevated temperature. Both compounds also proved to be very potent antagonists for rTRPV1, blocking in vivo the hypothermic action of capsaicin, consistent with their in vitro mechanism. The docking study of compounds 13S and 16S in our hTRPV1 homology model indicated that the binding modes differed somewhat, with that of 13S more closely resembling that of GRT12360.

Synthesis and p38 inhibitory activity of some novel substituted N,N′-diarylurea derivatives

We have identified a novel series of substituted N,N′-diarylurea p38α inhibitors. The inhibitory activity of the target compounds against the enzyme p38α, MAPKAPK2 in BHK cells, TNF-α release in LPS-stimulated THP-1 cells and p38α binding experiments were